Immunicum AB
Patent for the production of Immunicum’s therapeutic cancer vaccines to be granted in Europe
Immunicum AB 27.01.2015 15:10 Dissemination of a Adhoc News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Gothenburg, Sweden, 2015-01-27 15:10 CET (GLOBE NEWSWIRE) -- Immunicum AB (publ) today announced that the European Patent Office (EPO) has announced its intention to grant a patent pertaining to the production method of the Company's therapeutic cancer vaccines. - We are pleased with the positive news from the European Patent Office, which will further strengthen the intellectual property protection for our therapeutic cancer vaccines, says Jamal El-Mosleh, CEO of Immunicum. The announcement from the EPO relates to a patent titled 'Co-Differentiation Of Monocytes From Allogeneic Donors', covering a significant part of the production method of Immunicum's therapeutic cancer vaccines. Immunicum's vaccine cells are comprised of white blood cells from healthy blood donors, so-called allogeneic dendritic cells, which via a unique refinement process are developed into highly immunogenic cells. The Company's unique vaccine concept is based on over 30 years of research in the field of transplantation immunology and uses a new method to activate the body's own immune system to attack tumor cells. For further information, please contact: Jamal El-Mosleh, CEO, Immunicum Phone: +46 (0) 31 41 50 52 jamal.el-mosleh@immunicum.com The company's Certified Adviser is Redeye AB Phone: +46 (0) 8 545 013 31. www.redeye.se About Immunicum AB (publ) Immunicum AB (publ) develops vaccines for the treatment of tumor diseases. A phase II study of the company's most advanced project - INTUVAX(R) against renal cancer - is expected to start in early 2015. The project portfolio contains three further projects, including a clinical phase I/II-study in liver cancer. www.immunicum.com News Source: NASDAQ OMX 27.01.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Immunicum AB Sweden Phone: Fax: E-mail: Internet: ISIN: SE0005003654 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden